N-[2-(2,4,6-trichlorophenoxy)ethyl]propan-1-amine

We are N-[2-(2,4,6-trichlorophenoxy)ethyl]propan-1-amine CAS:67747-01-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N-[2-(2,4,6-trichlorophenoxy)ethyl]propan-1-amine
CAS.NO:67747-01-7
Synonyms:N-[2-(2,4,6-trichlorophenoxy)ethyl]propan-1-amine
 
Physical and Chemical Properties:
emical & Physical Properties
Density 1.26g/cm3
Boiling Point 361.1ºC at 760 mmHg
Molecular Formula C11H14Cl3NO
Molecular Weight 282.59400
Flash Point 172.2ºC
Index of Refraction 1.534
 
Specification:
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Prochloraz(CAS:67747-09-5).

N-[2-(2,4,6-trichlorophenoxy)ethyl]propan-1-amine


Related News: Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.71675-86-0 Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.98-82-8 It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.(3S)-3-[4-[(5-bromo-2-chlorophenyl)methyl]phenoxy]oxolane It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
2-(acetylamino)-2-[2-(4-octylphenyl)-2-oxo-ethyl]propanedioic acid diethyl ester View Details
4,4′-Dimethoxytrityl chloride View Details
2-Chlorobenzene-1,4-Diammonium Sulphate View Details
2,6-Dichloro-4-(trifluoromethyl)nicotinonitrile manufacturer 2′,3′-Dideoxyuridine manufacturer 3-(3,4-dihydroxyphenyl)propanoic acid Cas:1078-61-1 manufacturer 4-(2-Pyridinyl)benzaldehyde manufacturer Furfural manufacturer